Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. - Wikidata - awgldk - TriplyDB

Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.

Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.

http://www.wikidata.org/entity/Q34663499

about

Immunobiology of hepatocarcinogenesis: Ways to go or almost there?Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection Progress in systemic therapy of advanced hepatocellular carcinoma Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?Hepatobiliary Tumors: Update on Diagnosis and Management The Role of Autophagy in Hepatocellular Carcinoma Optimal combination of antiangiogenic therapy for hepatocellular carcinoma Hepatocellular carcinoma: Consensus, controversies and future directions. A report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting Recent advances in multidisciplinary management of hepatocellular carcinoma Hepatocellular Cancer: New Kids on the Block Oncological Impact of M-Tor Inhibitor Immunosuppressive Therapy after Liver Transplantation for Hepatocellular Carcinoma: Review of the Literature Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update First- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma-An Update on Patient Selection and Response Evaluation Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma Challenges of advanced hepatocellular carcinoma Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment Recent advances in hepatocellular carcinoma therapy.Short-term and long-term efficacy of 7 targeted therapies for the treatment of advanced hepatocellular carcinoma: a network meta-analysis: Efficacy of 7 targeted therapies for AHCC.Comparison of hepatocellular carcinoma in Eastern versus Western populations.Regression of hepatocellular carcinoma after treatment of hepatitis C: a case report.Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers.Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma.A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma.Systemic therapy for advanced hepatocellular carcinoma: an update.Evolving role of Sorafenib in the management of hepatocellular carcinoma.The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014 Drug development for hepatocellular carcinoma: knowing the past helps to understand the future Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out.Minimally invasive local therapies for liver cancer Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges.The over-expression of survivin enhances the chemotherapeutic efficacy of YM155 in human hepatocellular carcinoma.Epithelial to mesenchymal transition in the liver field: the double face of Everolimus in vitro.Neoadjuvant chemotherapy (NCT) plus targeted agents versus NCT alone in colorectal liver metastases patients: A systematic review and meta-analysis Additive Anti-Tumor Effects of Lovastatin and Everolimus In Vitro through Simultaneous Inhibition of Signaling Pathways Liver cancer: Approaching a personalized care.Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: A review and meta-analysis of prophylaxis management.Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.

P2860

Q26738293-9A4E4764-0CDA-4B35-A9A3-DA8BFD019FDA Q26738860-975AB82E-82E2-4C85-A683-B47CE6B77813 Q26740217-32A57E54-4C99-4EBF-BC49-BF560C0C99F3 Q26741201-11552700-C7F5-48FF-80E1-FF0778520D97 Q26766689-1195020F-EF17-4060-9EF9-D6D9EA724E51 Q26775654-1A48E2DC-609F-4BF3-92C8-D85C2432AD5D Q26777419-3011632D-30E5-4272-8CE4-1800DFBB235B Q26799458-28DD41CC-0310-427A-91F8-F301BDACF13F Q26828407-7A2236BD-1AFC-47B9-8FC1-5A68456CCFC9 Q26863748-8396C2C2-1E68-4901-81FC-3F305C4EE4A4 Q27022642-283497CB-D351-445F-BC32-AC79C9974BBD Q28067445-BFA727AD-6D26-4610-AF21-CE5964269361 Q28067598-33888244-8451-44D2-8797-5B7A49F931FE Q28073654-E07E8820-F786-4C79-AE1A-D25CC9B14D81 Q28075305-0C35AD1D-47E1-49D3-A79A-DDC7E0D7FF63 Q28076867-3615D2F0-978B-4489-AD37-E2AD4EB2F3DE Q28079378-BE097B4E-93F3-4A19-B229-3815E20929F8 Q30236010-417E80C1-67B8-4927-9328-F274F1912B28 Q30240170-EBCC4DEB-7BE3-4915-A199-FE390279283E Q30245396-67C2BCDB-4CA0-4AB2-B872-C7F2A3B1567E Q30279258-CEF0A6C7-4463-48EF-8F44-5240008008F4 Q33422744-A3394B90-DB66-4115-8449-CB0B21FAA575 Q33422778-5CC91183-9B04-4626-83B7-94E3720C6357 Q33433311-41FB7038-2454-477B-B77C-2079F73B59D4 Q33442349-D80B4F2A-E334-4A36-98DE-63D92A6A70E0 Q33593213-0C0ABA00-93DA-4C16-8E94-AFCB505DA7C3 Q33779864-B59907DB-30B6-4243-9BA8-04A81AA8B705 Q34402325-B97B733A-B1F3-4342-B667-F91882604F2C Q34458068-58C97566-0DA3-4F95-AF2F-AACCF25142D4 Q34728237-40E43EEB-99E6-44BE-BD9C-AC2BE753D731 Q34974386-2BFD736D-8D92-4C25-8C44-6E5693DF6E00 Q35501246-ECA83388-21BF-49D1-B007-812FA1D573C6 Q35742449-78F950D9-4CCD-4CEA-8881-352177E6DCDF Q35775057-5CB5251C-CB02-4EB2-B53C-ADB487B618DB Q35826810-1C8F4ADC-54EE-4FCC-8C22-560F8D589AEA Q35860831-B76B768F-52C1-4D50-811D-27C661361525 Q35903794-F816A702-4FEE-4692-AD50-AD018598C009 Q36009272-0D92AEDA-AFF2-4826-9899-356EF8209545 Q36245362-A00C612D-5B40-41E1-BD0D-CD48CD5507AC Q36381360-5070380C-DD14-4481-81EA-1390E581E145

P2860

Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.

http://www.wikidata.org/entity/Q34663499

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Effect of everolimus on surviv ...... E-1 randomized clinical trial.

@ast

Effect of everolimus on surviv ...... E-1 randomized clinical trial.

@en

Effect of everolimus on surviv ...... E-1 randomized clinical trial.

@nl

type

label

Effect of everolimus on surviv ...... E-1 randomized clinical trial.

@ast

Effect of everolimus on surviv ...... E-1 randomized clinical trial.

@en

Effect of everolimus on surviv ...... E-1 randomized clinical trial.

@nl

prefLabel

Effect of everolimus on surviv ...... E-1 randomized clinical trial.

@ast

Effect of everolimus on surviv ...... E-1 randomized clinical trial.

@en

Effect of everolimus on surviv ...... E-1 randomized clinical trial.

@nl

P1433

Q34663499-F4560866-9FD5-4B0C-9D33-642CC3C5D18B

P1476

Q34663499-AF3D915C-B53C-4AE5-A201-279ED2AAD089

P2093

Q34663499-0B345DE5-D763-4329-806C-1ED4AA4E00C7

Q34663499-103B26CE-6064-4C31-B982-92AE23DF280C

Q34663499-253F6889-2C2E-42AB-AC52-5D628E584D8D

Q34663499-2F465F6D-FF60-42DA-A62A-0D24F53BB8AA

Q34663499-4A531C6D-E80A-47D5-97D4-8D46DCE63469

Q34663499-588D3D66-EC2C-4F44-A29C-E9DBC5ED4586

Q34663499-7F38D8ED-8061-4535-B602-75070B7A7862

Q34663499-99119A19-5912-450B-9425-1341A577ADFA

Q34663499-9FDCC060-DFB8-48AE-B051-32385B1C7E17

Q34663499-A627BC76-D60F-4523-9B93-B61E7E58F946

P304

Q34663499-8C0BAE6E-4A44-4762-8978-1B1DC8F6F8B8

P31

Q34663499-B1FCF40B-1F8C-495F-A079-FB6AD5489505

P356

Q34663499-9CF45CAD-7C7C-412C-92D0-B9FF1DEAC7DE

P407

Q34663499-149A2F19-0600-4FAC-B749-BAECE109B6C3

P433

Q34663499-9E365A73-B11B-45E7-B5DD-25A170FAF029

P478

Q34663499-E57C7631-F0C5-4A6F-8508-C9CEEE3E9418

P50

Q34663499-292AE555-C5EF-414B-A048-857C4215BD88

Q34663499-A82770EE-2AC7-48AC-B86E-28E33565A517

Q34663499-E219A3C7-6D95-4661-8781-6DC8A2157E4A

P577

Q34663499-C3B19D1A-91BD-445F-8D7C-DB804EAA5D53

P5875

Q34663499-C3F24E4D-1A02-4F32-8AC5-A995F7B9B37B

P698

Q34663499-790E6A15-9517-4A51-8B69-6BB3224C58BE

P356

P1433

Journal of the American Medical Association

P1476

Effect of everolimus on surviv ...... E-1 randomized clinical trial.

@en

P2093

Andrew X Zhu

http://www.w3.org/2001/XMLSchema#string

Annette Jappe

http://www.w3.org/2001/XMLSchema#string

Arndt Vogel

http://www.w3.org/2001/XMLSchema#string

Bruno Daniele

http://www.w3.org/2001/XMLSchema#string

Chao-Long Chen

http://www.w3.org/2001/XMLSchema#string

Dalila B Sellami

http://www.w3.org/2001/XMLSchema#string

Eric Assenat

http://www.w3.org/2001/XMLSchema#string

Etienne Dorval

http://www.w3.org/2001/XMLSchema#string

Ho Yeong Lim

http://www.w3.org/2001/XMLSchema#string

Jean-Frederic Blanc

http://www.w3.org/2001/XMLSchema#string

P304

57-67

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.2014.7189

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

312

http://www.w3.org/2001/XMLSchema#string

P50

Markus Peck-Radosavljevic

Armando Santoro

P577

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263544619

http://www.w3.org/2001/XMLSchema#string

P698

25058218

http://www.w3.org/2001/XMLSchema#string